IL102460A - Method for enhancing the immunotherapeutic activity of lymphocytes to decrease the tumor burden by stimulation of lymphocytes in vitro in the presence of anti-cd3-antibody and by co-administration of il-2, kits containing such enhanced lymphocytes and their use in preparation of a medicament for cancer therapy - Google Patents
Method for enhancing the immunotherapeutic activity of lymphocytes to decrease the tumor burden by stimulation of lymphocytes in vitro in the presence of anti-cd3-antibody and by co-administration of il-2, kits containing such enhanced lymphocytes and their use in preparation of a medicament for cancer therapyInfo
- Publication number
- IL102460A IL102460A IL10246092A IL10246092A IL102460A IL 102460 A IL102460 A IL 102460A IL 10246092 A IL10246092 A IL 10246092A IL 10246092 A IL10246092 A IL 10246092A IL 102460 A IL102460 A IL 102460A
- Authority
- IL
- Israel
- Prior art keywords
- lymphocytes
- vitro
- decrease
- antibody
- stimulation
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title abstract 8
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000001024 immunotherapeutic effect Effects 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 238000011260 co-administration Methods 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72810791A | 1991-07-10 | 1991-07-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL102460A0 IL102460A0 (en) | 1993-01-14 |
IL102460A true IL102460A (en) | 2001-08-26 |
Family
ID=24925447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10246092A IL102460A (en) | 1991-07-10 | 1992-07-10 | Method for enhancing the immunotherapeutic activity of lymphocytes to decrease the tumor burden by stimulation of lymphocytes in vitro in the presence of anti-cd3-antibody and by co-administration of il-2, kits containing such enhanced lymphocytes and their use in preparation of a medicament for cancer therapy |
Country Status (12)
Country | Link |
---|---|
US (1) | US5316763A (xx) |
EP (1) | EP0593625B1 (xx) |
JP (1) | JP3507489B2 (xx) |
AT (1) | ATE142885T1 (xx) |
AU (1) | AU674128B2 (xx) |
CA (1) | CA2111564A1 (xx) |
DE (1) | DE69213943T2 (xx) |
IE (1) | IE922233A1 (xx) |
IL (1) | IL102460A (xx) |
MX (1) | MX9204077A (xx) |
WO (1) | WO1993000918A1 (xx) |
ZA (1) | ZA925155B (xx) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766920A (en) * | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
EP0440742B1 (en) * | 1988-10-27 | 1997-01-15 | The Regents Of The University Of Minnesota | Liposome immunoadjuvants containing il-2 |
US5556763A (en) * | 1992-04-06 | 1996-09-17 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Evaluation and treatment of patients with progressive immunosuppression |
AU1524095A (en) * | 1994-01-27 | 1995-08-15 | Cellcor, Inc. | Ex vivo activation of immune cells |
WO1995032729A1 (en) * | 1994-05-31 | 1995-12-07 | Augusto Carlos Ochoa | Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity |
US6033661A (en) | 1995-06-07 | 2000-03-07 | Thomas Jefferson University | Composition and method for allogenetic mononuclear cell immunotherapy |
US5723503A (en) * | 1994-09-28 | 1998-03-03 | Thomas Jefferson University | Biological treatment for rheumatoid arthritis |
AU6104396A (en) * | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Therapeutic uses of monoclonal antibody ta99 in combination with interleukin-2 and/or lymphokine activated killer cells |
US20020182730A1 (en) * | 1995-07-26 | 2002-12-05 | Micheal L. Gruenberg | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
WO1998014206A1 (en) * | 1996-10-04 | 1998-04-09 | Thomas Jefferson University | T cells mediating an immune response and methods of use |
US6787132B1 (en) * | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
FR2821947B1 (fr) * | 2001-03-12 | 2003-05-16 | Canon Kk | Procede et dispositif de validation de parametres definissant une image |
US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
US20030134341A1 (en) * | 2001-09-19 | 2003-07-17 | Medcell Biologics, Llc. | Th1 cell adoptive immunotherapy |
US20030175272A1 (en) * | 2002-03-07 | 2003-09-18 | Medcell Biologics, Inc. | Re-activated T-cells for adoptive immunotherapy |
US20050169970A1 (en) * | 2004-02-02 | 2005-08-04 | Unilever Bestfoods, North America | Food composition with fibers |
JP6074916B2 (ja) * | 2012-05-22 | 2017-02-08 | 東洋製罐グループホールディングス株式会社 | 細胞活性化方法、及び細胞培養方法 |
CN107502589A (zh) * | 2017-08-04 | 2017-12-22 | 北京世纪劲得生物技术有限公司 | 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0049611B2 (en) * | 1980-10-02 | 1993-12-08 | Hooper Trading Co. N.V. | A T-cell growth factor, and a process of producing the same |
US4464355A (en) * | 1981-03-26 | 1984-08-07 | Hooper Trading Co. | Serum-free and mitogen-free T-cell growth factor and process for making same |
US4683199A (en) * | 1983-01-31 | 1987-07-28 | Sloan-Kettering Institute For Cancer Research | Interleukin-2 dependent cytotoxic T-cell clones |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
GB8405555D0 (en) * | 1984-03-02 | 1984-04-04 | Rees A D M | Macrophage activating factors |
US4604377A (en) * | 1984-03-28 | 1986-08-05 | Cetus Corporation | Pharmaceutical compositions of microbially produced interleukin-2 |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
EP0203403B1 (en) * | 1985-05-01 | 1992-10-28 | Asahi Kasei Kogyo Kabushiki Kaisha | A cloned t cell capable of recognizing tumors and a t cell antigen receptor |
US4690915A (en) * | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
WO1988000970A2 (en) * | 1986-08-08 | 1988-02-11 | Regents Of The University Of Minnesota | Method of culturing leukocytes |
US4808151A (en) * | 1987-04-27 | 1989-02-28 | E. I. Du Pont De Nemours And Company | Simplified method for the preparation of human lymphokine activated killer cells |
US4882424A (en) * | 1987-05-11 | 1989-11-21 | Dana-Farber Cancer Institute, Inc. | Activation antigen |
WO1989005657A1 (en) * | 1987-12-17 | 1989-06-29 | Browning's Clinical Pathology Services Limited | Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection |
FI105320B (fi) * | 1988-04-04 | 2000-07-31 | Oncogen | Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa |
JPH03503844A (ja) * | 1988-04-15 | 1991-08-29 | リサーチ コーポレーシヨン テクノロジーズ インコーポレーテツド | Lak細胞サイトトキシン |
WO1990004633A1 (en) * | 1988-10-21 | 1990-05-03 | Brigham And Women's Hospital | ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR |
EP0440742B1 (en) * | 1988-10-27 | 1997-01-15 | The Regents Of The University Of Minnesota | Liposome immunoadjuvants containing il-2 |
GR1001034B (el) * | 1989-07-21 | 1993-03-31 | Ortho Pharma Corp | Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος. |
US5126132A (en) * | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
-
1992
- 1992-07-09 IE IE223392A patent/IE922233A1/en not_active Application Discontinuation
- 1992-07-10 MX MX9204077A patent/MX9204077A/es not_active IP Right Cessation
- 1992-07-10 EP EP92915210A patent/EP0593625B1/en not_active Expired - Lifetime
- 1992-07-10 IL IL10246092A patent/IL102460A/xx not_active IP Right Cessation
- 1992-07-10 CA CA002111564A patent/CA2111564A1/en not_active Abandoned
- 1992-07-10 WO PCT/US1992/005673 patent/WO1993000918A1/en active IP Right Grant
- 1992-07-10 AU AU23005/92A patent/AU674128B2/en not_active Ceased
- 1992-07-10 DE DE69213943T patent/DE69213943T2/de not_active Expired - Fee Related
- 1992-07-10 AT AT92915210T patent/ATE142885T1/de active
- 1992-07-10 JP JP50237893A patent/JP3507489B2/ja not_active Expired - Fee Related
- 1992-07-10 ZA ZA925155A patent/ZA925155B/xx unknown
- 1992-07-10 US US07/910,835 patent/US5316763A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1993000918A1 (en) | 1993-01-21 |
ZA925155B (en) | 1993-04-28 |
JP3507489B2 (ja) | 2004-03-15 |
EP0593625A4 (en) | 1994-11-02 |
JPH07502486A (ja) | 1995-03-16 |
AU674128B2 (en) | 1996-12-12 |
ATE142885T1 (de) | 1996-10-15 |
AU2300592A (en) | 1993-02-11 |
DE69213943T2 (de) | 1997-04-10 |
MX9204077A (es) | 1994-06-30 |
EP0593625B1 (en) | 1996-09-18 |
EP0593625A1 (en) | 1994-04-27 |
DE69213943D1 (de) | 1996-10-24 |
US5316763A (en) | 1994-05-31 |
IL102460A0 (en) | 1993-01-14 |
CA2111564A1 (en) | 1993-01-21 |
IE922233A1 (en) | 1993-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL102460A (en) | Method for enhancing the immunotherapeutic activity of lymphocytes to decrease the tumor burden by stimulation of lymphocytes in vitro in the presence of anti-cd3-antibody and by co-administration of il-2, kits containing such enhanced lymphocytes and their use in preparation of a medicament for cancer therapy | |
Marquet et al. | Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site | |
EP0256714A3 (en) | Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2 | |
ES2454990T3 (es) | Quimioterapia e inmunoterapia simultáneas | |
MY112405A (en) | Method of tumer treatment. | |
Lichtor et al. | Prolonged survival of mice with glioma injected intracerebrally with double cytokine—secreting cells | |
NZ210867A (en) | Tumour-specific monoclonal antibodies, production thereof and use | |
EP0702563A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND HYPERPROLIFERATIVE DISEASES | |
AR004445A1 (es) | Una composicion inmunogenica, una dosis unitaria, un metodo para producir la composicion, un kit para producir la composicion, una poblacion de celulas,uso de dicha poblacion celular y una preparacion combinada | |
EP0719150A4 (en) | CELL VACCINE AND METHODS OF USE IN THE TREATMENT OF SOLID MALIGNANT TUMORS | |
MX2023003414A (es) | Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y metodos de uso de las mismas. | |
CN102196815A (zh) | 使用辐射和免疫细胞因子的癌症治疗 | |
Cerkovnik et al. | Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity | |
RU93042874A (ru) | Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии | |
JPH03504854A (ja) | 細胞毒素療法 | |
CA2081043A1 (en) | Antitumor vaccines comprising il-6 transfected cells | |
Weiss et al. | A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma | |
Bradford et al. | The chemotherapeutic response of a murine (VM) model of human glioma | |
WO1996036354A3 (en) | Anticancer vaccine comprising il6/il6 receptor transfected cells | |
CN116832152A (zh) | 免疫检查点抑制剂组合物及其应用 | |
Scheibenbogen et al. | Phase II study of intermittent low-dose IFN-gamma in metastatic renal cell cancer | |
JPS63295516A (ja) | 基底細胞癌の治療のためのヒトγ−インターフェロンの使用 | |
UA15070A (uk) | Спосіб лікуваhhя злоякісhих пухлиh у людей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |